US Patent Covering Amplification Consumables Granted to Enigma Diagnostics Limited

OXFORD, England and SAN DIEGO, April 19, 2010 - Enigma Diagnostics Limited, the decentralised and point-of-care molecular
diagnostics company, announced today that the U.S. Patent and Trademark
Office has granted U.S. Patent No. 7,659,096 with claims that cover the use
of amplification consumables in several current real-time and end point PCR
instruments. The consumables incorporate a thermally conducting layer and
reaction wells in combination with a reaction mixture and a blocking agent.
Enigma Diagnostics Ltd is the exclusive licensee of this patent from the UK
Defence Science Technology Laboratory.

This is the most recent patent to issue in Enigma's expanding portfolio
of over 300 patents and patent applications. This portfolio includes patents
relating to intelligent sample preparation consumables and novel
amplification technologies for current and 'next generation' molecular
diagnostic systems and sample preparation devices. Enigma continues to expand
its worldwide licensing programme and awareness of its broadly applicable and
important IP portfolio which now includes this US patent.

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation
rapid molecular diagnostic instrument platforms for decentralized and
point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and
sensitivity of real-time PCR (polymerase chain reaction) with the simplicity
needed for decentralized and point-of-care testing providing results from a
raw sample in less than 60 minutes. The Company is targeting a number of
multi-billion pound markets, core among which are the Clinical and high-value
Applied Markets. Enigma's commercialisation strategy is to maximize revenues
from a continuous flow of market leading rapid diagnostic point-of-care
instrument and assay platforms, based on unique technologies and underpinned
by its broad Intellectual Property portfolio. Enigma will partner with market
leaders where global penetration of markets is required and where
appropriate, will engage regional partners and build in-house sales and
marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology
Laboratory to a portfolio of patents, which represent over 15 years of UK
Ministry of Defence funded Research. It also has licences from Applied
Biosystems and Celera Diagnostics for commercialisation of real-time PCR
instruments, and from Roche Molecular Systems to practise HybProbe real-time
PCR chemistry for human and veterinary in vitro diagnostics. Enigma's
in-house RandD activities have generated a portfolio of worldwide patent
families dedicated to real-time PCR and wider molecular technologies. Many of
these patents are granted across a range of core commercial territories
including US, EU and Japan with more extensive filing and grants across a
number of other key territories.

For more information visit www.enigmadiagnostics.com

    Contacts
    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44-1980-590131

    US Contact:
    Tiberend Strategic Advisors, Inc.
    +1-212-827-0020
    Tamara Bright
    tbright@tiberendstrategicadvisors.com

UK Contact: Deborah Cordingley, Enigma Diagnostics, +44-1980-590131, deborah.cordingley at enigmadiagnostics.com; US Contact: Tamara Bright, Tiberend Strategic Advisors, Inc., +1-212-827-0020, tbright at tiberendstrategicadvisors.com